Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer

Journal of Clinical Oncology

Volumn 32, Issue 14, 2014, Pages 1507-1515

  Moran, Meena S ^a   Schnitt, Stuart J ^b   Giuliano, Armando E ^c   Harris, Jay R ^b   Khan, Seema A ^d   Horton, Janet ^e   Klimberg, Suzanne ^f   Chavez MacGregor, Mariana ^g   Freedman, Gary ^h   Houssami, Nehmat ⁱ   Johnson, Peggy L ^j   Morrow, Monica ^k  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j Susan G Komen Advocate in Science   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INK;

ADULT; ARTICLE; BIOLOGICAL THERAPY; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CLINICAL PRACTICE; CONFLICT OF INTEREST; CONSENSUS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EVIDENCE BASED PRACTICE; HUMAN; INTRADUCTAL CARCINOMA; MEDICAL SOCIETY; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PARTIAL MASTECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RADIATION DOSE; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; WHOLE BREAST RADIATION THERAPY; YOUNG ADULT; BREAST TUMOR; FEMALE; ONCOLOGY; SEGMENTAL MASTECTOMY; STANDARD; TUMOR INVASION;

BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RADIATION ONCOLOGY;

EID: 84902507205     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.3935     Document Type: Article

References (71)

1. Darby S, McGale P, Correa C, et al: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707-1716, 2011
2. Fisher B, Anderson S, Bryant J, et al: Twentyyear follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233-1241, 2002 (Pubitemid 35176242)
3. Azu M, Abrahamse P, Katz SJ, et al: What is an adequate margin for breast-conserving surgery? Surgeon attitudes and correlates. Ann Surg Oncol 17:558-563, 2010
4. Taghian A, Mohiuddin M, Jagsi R, et al: Current perceptions regarding surgical margin status after breast-conserving therapy: Results of a survey. Ann Surg 241:629-639, 2005 (Pubitemid 40397311)
5. McCahill LE, Single RM, Aiello Bowles EJ, et al: Variability in reexcision following breast conservation surgery. JAMA 307:467-475, 2012
6. Morrow M, Jagsi R, Alderman AK, et al: Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA 302:1551-1556, 2009
7. King TA, Sakr R, Patil S, et al: Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 29:2158-2164, 2011
8. Anderson S, Wapnir I, Dignam J, et al: Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol 27:2466-2473, 2009
9. Institute of Medicine: Clinical Practice Guidelines We Can Trust. Washington, DC, National Academies Press, 2011
10. Houssami N, Macaskill P, Marinovich ML, et al: Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer 46:3219-3232, 2010
11. Houssami N, Macaskill P, Marinovich ML, et al: The association of surgical margins and local recurrence in women with early stage invasive breast cancer treated with breast conserving therapy: A metaanalysis. Ann Surg Oncol (in press)
12. Sardanelli F, Podo F, Santoro F, et al: Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the High Breast Cancer Risk Italian 1 Study): Final results. Invest Radiol 46:94-105, 2011
13. Moher D, Liberati A, Tetzlaff J, et al: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol 62:1006-1012, 2009
14. Bellon JR, Come SE, Gelman RS, et al: Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: Updated results of a prospective randomized trial. J Clin Oncol 23:1934-1940, 2005 (Pubitemid 46211372)
15. Voogd AC, Nielsen M, Peterse JL, et al: Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: Pooled results of two large European randomized trials. J Clin Oncol 19:1688-1697, 2001 (Pubitemid 32230869)
16. Wazer DE, Schmidt-Ullrich RK, Ruthazer R, et al: Factors determining outcome for breast-conserving irradiation with margin-directed dose escalation to the tumor bed. Int J Radiat Oncol Biol Phys 40:851-858, 1998 (Pubitemid 28150803)
17. Mansfield CM, Komarnicky LT, Schwartz GF, et al: Ten-year results in 1070 patients with stages I and II breast cancer treated by conservative surgery and radiation therapy. Cancer 75:2328-2336, 1995
18. Bartelink H, Horiot JC, Poortmans PM, et al: Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 25:3259-3265, 2007 (Pubitemid 47325610)
19. Jones HA, Antonini N, Hart AA, et al: Impact of pathological characteristics on local relapse after breast-conserving therapy: A subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol 27:4939-4947, 2009
20. Holland R, Veling SH, Mravunac M, et al: Histologic multifocality of Tis, T1-2 breast carcinomas implications for clinical trials of breast-conserving surgery. Cancer 56:979-990, 1985 (Pubitemid 15003474)
21. Graham RA, Homer MJ, Katz J, et al: The pancake phenomenon contributes to the inaccuracy of margin assessment in patients with breast cancer. Am J Surg 184:89-93, 2002 (Pubitemid 34880211)
22. Guidi AJ, Connolly JL, Harris JR, et al: The relationship between shaved margin and inked margin status in breast excision specimens. Cancer 79:1568-1573, 1997 (Pubitemid 27154789)
23. Carter D: Margins of "lumpectomy" for breast cancer. Hum Pathol 17:330-332, 1986
24. Fisher B, Jeong JH, Anderson S, et al: Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: Updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst 96:1823-1831, 2004 (Pubitemid 40089466)
25. Mamounas EP, Anderson SJ, Dignam JJ, et al: Predictors of locoregional recurrence after neoadjuvant chemotherapy: Results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 30:3960-3966, 2012
26. Hind D, Ward S, De Nigris E, et al: Hormonal therapies for early breast cancer: Systematic review and economic evaluation. Health Technol Assess 11:iii-iv, ix-xi, 1-134, 2007
27. Smith I, Procter M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36, 2007 (Pubitemid 46039831)
28. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
29. Mannino M, Yarnold JR: Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: Can radiotherapy ever be safely withheld? Radiother Oncol 90: 14-22, 2009
30. Arvold ND, Taghian AG, Niemierko A, et al: Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 29:3885-3891, 2011
31. Voduc KD, Cheang MC, Tyldesley S, et al: Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684-1691, 2010
32. Mazouni C, Rimareix F, Mathieu MC, et al: Outcome in breast molecular subtypes according to nodal status and surgical procedures. Am J Surg 205:662-667, 2013
33. Haffty BG, Yang Q, Reiss M, et al: Locoregional relapse and distant metastasis in conservatively managed triple-negative early-stage breast cancer. J Clin Oncol 24:5652-5657, 2006 (Pubitemid 46631305)
34. Freedman GM, Anderson PR, Li T, et al: Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer 115:946-951, 2009
35. Gangi A, Chung A, Mirocha J, et al: Breast-conserving therapy is appropriate local management of triple negative breast cancer. JAMA Surg (in press)
36. Pilewskie ML, Ho A, Orell E, et al: Effect of margin width on local recurrence in triple-negative breast cancer patients treated with breast-conserving surgery. Ann Surg Oncol [epub ahead of print on December 11, 2013]
37. Abdulkarim BS, Cuartero J, Hanson J, et al: Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 29:2852-2858, 2011
38. Ho AY, Gupta G, King TA, et al: Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer 118:4944-4952, 2012
39. Adkins FC, Gonzalez-Angulo AM, Lei X, et al: Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol 18:3164-3173, 2011
40. Formenti SC, Gidea-Addeo D, Goldberg JD, et al: Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol 25:2236-2242, 2007 (Pubitemid 46954649)
41. Donovan E, Bleakley N, Denholm E, et al: Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 82:254-264, 2007 (Pubitemid 46341474)
42. Formenti SC, DeWyngaert JK, Jozsef G, et al: Prone vs supine positioning for breast cancer radiotherapy. JAMA 308:861-863, 2012
43. Pignol JP, Olivotto I, Rakovitch E, et al: A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 26:2085-2092, 2008
44. Whelan TJ, Pignol JP, Levine MN, et al: Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362:513-520, 2010
45. Haviland J, Agrawal R, Aird E, et al: The UK START (Standardisation of Breast Radiotherapy) trials: 10-year follow-up results. Cancer Res 72, 2012 (suppl; abstr S4-1)
46. Bentzen SM, Agrawal RK, Aird EG, et al: The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet Oncol 9:331-341, 2008
47. Bentzen SM, Agrawal RK, Aird EG, et al: The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet 371:1098-1107, 2008
48. Polgár C, Fodor J, Orosz Z, et al: Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer first results of the randomized Budapest boost trial. Strahlenther Onkol 178:615-623, 2002 (Pubitemid 35390398)
49. Romestaing P, Lehingue Y, Carrie C, et al: Role of a 10-Gy boost in the conservative treatment of early breast cancer: Results of a randomized clinical trial in Lyon, France. J Clin Oncol 15:963-968, 1997 (Pubitemid 27106278)
50. Livi L, Meattini I, Franceschini D, et al: Radiotherapy boost dose-escalation for invasive breast cancer after breast-conserving surgery: 2093 patients treated with a prospective margin-directed policy. Radiother Oncol 108:273-278, 2013
51. Neuschatz AC, DiPetrillo T, Safaii H, et al: Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy. Cancer 97:30-39, 2003 (Pubitemid 36033860)
52. Murphy C, Anderson PR, Li T, et al: Impact of the radiation boost on outcomes after breast-conserving surgery and radiation. Int J Radiat Oncol Biol Phys 81:69-76, 2011
53. Biglia N, Maggiorotto F, Liberale V, et al: Clinical-pathologic features, long term-outcome and surgical treatment in a large series of patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). Eur J Surg Oncol 39:455-460, 2013
54. Chung MA, Cole B, Wanebo HJ, et al: Optimal surgical treatment of invasive lobular carcinoma of the breast. Ann Surg Oncol 4:545-550, 1997 (Pubitemid 127725500)
55. Winchester DJ, Chang HR, Graves TA, et al: A comparative analysis of lobular and ductal carcinoma of the breast: Presentation, treatment, and outcomes. J Am Coll Surg 186:416-422, 1998 (Pubitemid 28169363)
56. Galimberti V, Maisonneuve P, Rotmensz N, et al: Influence of margin status on outcomes in lobular carcinoma: Experience of the European Institute of Oncology. Ann Surg 253:580-584, 2011
57. Sasson AR, Fowble B, Hanlon AL, et al: Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation. Cancer 91:1862-1869, 2001 (Pubitemid 32424112)
58. Ciocca RM, Li T, Freedman GM, et al: Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy. Ann Surg Oncol 15:2263-2271, 2008
59. Moran M, Haffty BG: Lobular carcinoma in situ as a component of breast cancer: The long-term outcome in patients treated with breast-conservation therapy. Int J Radiat Oncol Biol Phys 40:353-358, 1998 (Pubitemid 28114380)
60. Downs-Kelly E, Bell D, Perkins GH, et al: Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ. Arch Pathol Lab Med 135:737-743, 2011
61. de Bock GH, van der Hage JA, Putter H, et al: Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: Long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer 42:351-356, 2006 (Pubitemid 43132890)
62. Fisher ER, Anderson S, Tan-Chiu E, et al: Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer 91:1679-1687, 2001 (suppl) (Pubitemid 32319246)
63. Kroman N, Holtveg H, Wohlfahrt J, et al: Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 100:688-693, 2004 (Pubitemid 38176844)
64. Anders CK, Hsu DS, Broadwater G, et al: Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324-3330, 2008
65. Cancello G, Maisonneuve P, Rotmensz N, et al: Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol 21:1974-1981, 2010
66. Demirci S, Broadwater G, Marks LB, et al: Breast conservation therapy: The influence of molecular subtype and margins. Int J Radiat Oncol Biol Phys 83:814-820, 2012
67. Partridge AH, Gelber S, Piccart-Gebhart MJ, et al: Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: Results from a herceptin adjuvant trial. J Clin Oncol 31:2692-2698, 2013
68. Schnitt SJ, Connolly JL, Harris JR, et al: Pathologic predictors of early local recurrence in stage I and II breast cancer treated by primary radiation therapy. Cancer 53:1049-1057, 1984 (Pubitemid 14196481)
69. Schnitt SJ, Connolly JL, Khettry U, et al: Pathologic findings on re-excision of the primary site in breast cancer patients considered for treatment by primary radiation therapy. Cancer 59:675-681, 1987 (Pubitemid 17018739)
70. Holland R, Connolly JL, Gelman R, et al: The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J Clin Oncol 8:113-118, 1990 (Pubitemid 20032453)
71. Schnitt SJ, Abner A, Gelman R, et al: The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer 74:1746-1751, 1994 (Pubitemid 24301829)